First Time Loading...

Aldeyra Therapeutics Inc
NASDAQ:ALDX

Watchlist Manager
Aldeyra Therapeutics Inc Logo
Aldeyra Therapeutics Inc
NASDAQ:ALDX
Watchlist
Price: 3.97 USD 2.58% Market Closed
Updated: Apr 18, 2024

Intrinsic Value

ALDX's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Aldeyra Therapeutics, Inc. operates as a biotechnology company. [ Read More ]

The intrinsic value of one ALDX stock under the Base Case scenario is 0.92 USD. Compared to the current market price of 3.97 USD, Aldeyra Therapeutics Inc is Overvalued by 77%.

Key Points:
ALDX Intrinsic Value
Base Case
0.92 USD
Overvaluation 77%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Aldeyra Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ALDX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Aldeyra Therapeutics Inc

Provide an overview of the primary business activities
of Aldeyra Therapeutics Inc.

What unique competitive advantages
does Aldeyra Therapeutics Inc hold over its rivals?

What risks and challenges
does Aldeyra Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Aldeyra Therapeutics Inc recently?

Summarize the latest earnings call
of Aldeyra Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aldeyra Therapeutics Inc.

Provide P/S
for Aldeyra Therapeutics Inc.

Provide P/E
for Aldeyra Therapeutics Inc.

Provide P/OCF
for Aldeyra Therapeutics Inc.

Provide P/FCFE
for Aldeyra Therapeutics Inc.

Provide P/B
for Aldeyra Therapeutics Inc.

Provide EV/S
for Aldeyra Therapeutics Inc.

Provide EV/GP
for Aldeyra Therapeutics Inc.

Provide EV/EBITDA
for Aldeyra Therapeutics Inc.

Provide EV/EBIT
for Aldeyra Therapeutics Inc.

Provide EV/OCF
for Aldeyra Therapeutics Inc.

Provide EV/FCFF
for Aldeyra Therapeutics Inc.

Provide EV/IC
for Aldeyra Therapeutics Inc.

Show me price targets
for Aldeyra Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Aldeyra Therapeutics Inc?

How accurate were the past Revenue estimates
for Aldeyra Therapeutics Inc?

What are the Net Income projections
for Aldeyra Therapeutics Inc?

How accurate were the past Net Income estimates
for Aldeyra Therapeutics Inc?

What are the EPS projections
for Aldeyra Therapeutics Inc?

How accurate were the past EPS estimates
for Aldeyra Therapeutics Inc?

What are the EBIT projections
for Aldeyra Therapeutics Inc?

How accurate were the past EBIT estimates
for Aldeyra Therapeutics Inc?

Compare the revenue forecasts
for Aldeyra Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aldeyra Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aldeyra Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aldeyra Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Aldeyra Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Aldeyra Therapeutics Inc with its peers.

Analyze the financial leverage
of Aldeyra Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Aldeyra Therapeutics Inc.

Provide ROE
for Aldeyra Therapeutics Inc.

Provide ROA
for Aldeyra Therapeutics Inc.

Provide ROIC
for Aldeyra Therapeutics Inc.

Provide ROCE
for Aldeyra Therapeutics Inc.

Provide Gross Margin
for Aldeyra Therapeutics Inc.

Provide Operating Margin
for Aldeyra Therapeutics Inc.

Provide Net Margin
for Aldeyra Therapeutics Inc.

Provide FCF Margin
for Aldeyra Therapeutics Inc.

Show all solvency ratios
for Aldeyra Therapeutics Inc.

Provide D/E Ratio
for Aldeyra Therapeutics Inc.

Provide D/A Ratio
for Aldeyra Therapeutics Inc.

Provide Interest Coverage Ratio
for Aldeyra Therapeutics Inc.

Provide Altman Z-Score Ratio
for Aldeyra Therapeutics Inc.

Provide Quick Ratio
for Aldeyra Therapeutics Inc.

Provide Current Ratio
for Aldeyra Therapeutics Inc.

Provide Cash Ratio
for Aldeyra Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Aldeyra Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Aldeyra Therapeutics Inc?

What is the current Free Cash Flow
of Aldeyra Therapeutics Inc?

Financials

Balance Sheet Decomposition
Aldeyra Therapeutics Inc

Current Assets 147.8m
Cash & Short-Term Investments 142.8m
Other Current Assets 5m
Non-Current Assets 516.6k
PP&E 516.6k
Current Liabilities 22.3m
Accounts Payable 1.3m
Accrued Liabilities 5.8m
Other Current Liabilities 15.1m
Non-Current Liabilities 6.3m
Other Non-Current Liabilities 6.3m
Efficiency

Earnings Waterfall
Aldeyra Therapeutics Inc

Revenue
0 USD
Operating Expenses
-42.8m USD
Operating Income
-42.8m USD
Other Expenses
5.3m USD
Net Income
-37.5m USD

Free Cash Flow Analysis
Aldeyra Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ALDX Profitability Score
Profitability Due Diligence

Aldeyra Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

31/100
Profitability
Score

Aldeyra Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

ALDX Solvency Score
Solvency Due Diligence

Aldeyra Therapeutics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
49/100
Solvency
Score

Aldeyra Therapeutics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALDX Price Targets Summary
Aldeyra Therapeutics Inc

Wall Street analysts forecast ALDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALDX is 9.44 USD with a low forecast of 7.07 USD and a high forecast of 11.55 USD.

Lowest
Price Target
7.07 USD
78% Upside
Average
Price Target
9.44 USD
138% Upside
Highest
Price Target
11.55 USD
191% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ALDX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ALDX Price
Aldeyra Therapeutics Inc

1M 1M
+43%
6M 6M
+129%
1Y 1Y
-62%
3Y 3Y
-64%
5Y 5Y
-49%
10Y 10Y
-45%
Annual Price Range
3.97
52w Low
1.47
52w High
11.89
Price Metrics
Average Annual Return 3.69%
Standard Deviation of Annual Returns 43.75%
Max Drawdown -90%
Shares Statistics
Market Capitalization 235m USD
Shares Outstanding 58 895 800
Percentage of Shares Shorted 4.42%

ALDX Return Decomposition
Main factors of price return

What is price return decomposition?

ALDX News

Last Important Events
Aldeyra Therapeutics Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Aldeyra Therapeutics Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Aldeyra Therapeutics Inc Logo
Aldeyra Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

235m USD

Dividend Yield

0%

Description

Aldeyra Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Lexington, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2014-05-02. The firm's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). The company has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The firm's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses two biological mechanisms of action: reactive aldehyde species (RASP) modulation and dihydrofolate reductase inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation through down-regulation of immune cell activation or proliferation.

Contact

MASSACHUSETTS
Lexington
131 Hartwell Ave Ste 320
+17817614904.0
https://www.aldeyra.com/

IPO

2014-05-02

Employees

12

Officers

CEO, President & Director
Dr. Todd C. Brady M.D., Ph.D.
Senior VP of Finance, Interim CFO & Treasurer
Mr. Bruce Greenberg CPA, M.B.A.
Chief Development Officer
Dr. Stephen G. Machatha Ph.D.
Vice President of Commercial Strategy & Operations
Mr. Kelly Mizer
Head of Investor Relations
David Burke

See Also

Discover More
What is the Intrinsic Value of one ALDX stock?

The intrinsic value of one ALDX stock under the Base Case scenario is 0.92 USD.

Is ALDX stock undervalued or overvalued?

Compared to the current market price of 3.97 USD, Aldeyra Therapeutics Inc is Overvalued by 77%.